FOLFOX	Folinic acid, 5-fluorouracil, and oxaliplatin
FLAM	Flavopiridol, cytarabine, and mitoxantrone
SAR	Structure–activity relationship
BET	Bromodomain and extraterminal
PARP 1	Poly(ADP-ribose) polymerase 1
IC50	Half maximal inhibitory concentration
Bax	Bcl-2 associated X protein
Bcl-2	B-cell lymphoma 2
Topo IIα	Topoisomerase IIα
GI50	Concentration causing 50% growth inhibition
EGFR	Epidermal growth factor receptor
LD50	Concentration causing 50% cell death
MDR	Multidrug-resistant/resistance
P-gp	P-glycoprotein
ABC	ATP-binding cassette
BCR-ABL	Breakpoint Cluster Region–Abelson
CDK4, 6, and 9	Cyclin-dependent kinase 4, 6, and 9
PROTAC	Proteolysis Targeting Chimera
MRP1	Multidrug-resistance-associated protein 1
BCRP	Breast cancer resistance protein
EC50	Concentration producing 50% of the maximal effect
ADME	Absorption Distribution Metabolism Excretion
ADMET	Absorption Distribution Metabolism Excretion Toxicity
HIF-1α	Hypoxia inducible factor 1 α
HK2	Hexokinase 2
PKM2	M2-type pyruvate kinase
PFKP	Phosphofructokinase
VEGFR-2	Vascular endothelial growth factor receptor 2
BTK	Bruton’s tyrosine kinase
ER	Estrogen receptor
SERM	Selective estrogen receptor modulator
CC50	Concentration causing 50% cell cytotoxicity
TS	Tumor selectivity
PSE	Potency-selectivity expression
QSAR	Quantitative structure–activity relationship
Akt	Protein kinase B
BID	BH3-interacting-domain death agonist
CCND1	Cell cycle progression modulator cyclin D1
NADPH	Reduced nicotinamide adenine dinucleotide phosphate
NF-κB	Nuclear factor kappa-light-chain-enhancer of activated B cells
PI3K/mTOR	Phosphatidylinositol-4,5-bisphosphate 3-kinase/mechanistic target of rapamycin
RSK2	Ribosomal S6 kinase 2